Compare Five9 Inc (FIVN) vs 10X Genomics Inc (TXG) Price & Performance

Five9 (FIVN) trades at $25.05, down 2.07% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals, with revenue growing from $779M in 2022 to $1.15B in 2025 and turning profitable with net income of $39.42M. Recent news highlights AI product launches and workplace awards, while legal scrutiny on insider conduct persists.

The stock presents a positive outlook with strong analyst support (61% buy ratings) and a consensus price target of $27.00, offering ~8% upside. Key risks include negative net cash flow, high debt levels, and ongoing legal investigations into insider fiduciary duties that could pressure sentiment.

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.